Asset profile
Dolutegravir · Tivicay / Triumeq / Dovato / Juluca (component)
Small molecule
Evidence outlook
Approved: HIV
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
60 competitors in this universe: 6 direct rivals (same mechanism and indication), 0 same-class, 54 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Dolutegravir (Tivicay / Triumeq / Dovato / Juluca (component)): this drug | Approved | Small molecule | HIV integrase | ||
| Bictegravir (Biktarvy) | Approved | Small molecule | HIV integrase | ||
| Cabotegravir (Vocabria / Cabenuva / Apretude) | Approved | Small molecule | HIV integrase | ||
| Elvitegravir (Stribild / Genvoya (component)) | Approved | Small molecule | HIV integrase | ||
| Raltegravir (Isentress) | Approved | Small molecule | HIV integrase | ||
| VH4524184 | Phase 2 | Small molecule | HIV integrase | ||
| ACC017 | Phase 1/2 | Small molecule | HIV integrase | ||
| Crofelemer (Mytesi) | Approved | Small molecule | Chloride channel (intestinal epithelium) | ||
| Darunavir (Prezista) | Approved | Small molecule | HIV protease | ||
| Doravirine (Pifeltro) | Approved | Small molecule | HIV reverse transcriptase | ||
| Elsulfavirine (Elpida) | Approved | Small molecule | HIV reverse transcriptase | ||
| Emtricitabine / Tenofovir Disoproxil Fumarate (Truvada) | Approved | Small molecule | HIV reverse transcriptase | ||
| Etravirine (Intelence) | Approved | Small molecule | HIV reverse transcriptase | ||
| Fosamprenavir (Lexiva / Telzir) | Approved | Small molecule | HIV protease | ||
| Fostemsavir (Rukobia) | Approved | Small molecule | HIV gp120 | ||
| Ibalizumab (Trogarzo) | Approved | Monoclonal antibody | CD4 receptor |
…and 45 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(14 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (3)
November 2026 (1)
2027 (3)
February 2027 (1)
March 2027 (1)
May 2027 (1)
What to watch
2028 (6)
January 2028 (4)
What to watch
What to watch
May 2028 (1)
What to watch
October 2028 (1)
2029 (1)
June 2029 (1)
2032 (1)
September 2032 (1)
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.